Condition: AChR-Ab Seropositive Generalized Myasthenia Gravis · Myasthenia Gravis (MG) · MG - Myasthenia Gravis · Sponsor: argenx
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA2 is to investigate the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG). The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adaptforward2
This description comes directly from the study's public registry record.
Sabine Coppieters, MD · 857-350-4834 · clinicaltrials@argenx.com
Always discuss trial participation with your own doctor first.
| Visionary Investigators Network | Miami, Florida, United States | Recruiting |
| Erlanger Health System | Chattanooga, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07673627